Latest News
News
FDA: Gadolinium retention prompts new GBCA class warning, safety measures
Gadolinium-based contrast agents used for MRI will now carry a warning regarding potential retention in the bodies and brains of treated patients...
Conference Coverage
Zika RNA persists in blood components after clearance from plasma
Zika RNA can persist in blood components for about up to 3 months.
News
FDA: Laparoscopic power morcellators can spread malignant cells when used in women with occult uterine cancers*
The findings reinforce the FDA’s warnings that these devices shouldn’t be used to remove fibroids from some women.
From the Journals
Sequential chemotherapy and radiotherapy may be best in locally advanced NSCLC with negative margins
For patients with R0 pN2 NSCLC, median overall survival was 58.8 months for sequential chemotherapy followed by radiation, versus 40.4 months for...
Conference Coverage
HERCULES: Caplacizumab improved platelet response in aTTP
ATLANTA - Caplacizumab led to significantly faster platelet normalization and lower recurrence rates in acquired thrombotic thrombocytopenic...
From the Journals
Rare neurological complication linked to Waldenstrom disease
A 67-year-old man with Waldenstrom disease experienced bilateral facial nerve palsy.
Conference Coverage
Postmenopausal women who shed pounds see lower breast cancer risk
SAN ANTONIO – Compared with peers who had stable weight, women who lost at least 5% of their body weight had a lower risk of invasive breast...
Conference Coverage
High rate of arm morbidity in young breast cancer survivors
SAN ANTONIO – A significant rate of arm swelling and decreased range of motion was seen in young breast cancer patients 1 year after surgery.
From the Journals
Rituximab may be best choice for splenic MZL
Rituximab monotherapy appears to outperform splenectomy based on retrospective data.
Conference Coverage
Zika virus testing shows low incidence in donor blood outside of high-infection areas
Several studies show incidence of Zika in donor blood correlated to local incidence of disease.
Conference Coverage
CRB-410 update: Multiple myeloma response rates remain high with bb2121 CAR T-cell therapy
ATLANTA – A novel CAR T-cell therapy that targets BCMA shows promising efficacy and safety in heavily pretreated patients with relapsed/refractory...